Introduction: Penile cancer (PC) is a rare malignancy in developed countries but presents significantly higher incidence rates in developing regions such as Northern and Northeastern Brazil, where it accounts for approximately 2.1% of malignant neoplasms in men. This distribution reflects regional disparities in access to healthcare services, socioeconomic conditions, and the effectiveness of public prevention policies. The predominant histopathological subtype is squamous cell carcinoma (SCC), whose etiopathogenesis is frequently associated with human papillomavirus (HPV) infection, especially genotype 16, known for its high oncogenic potential. Viral carcinogenesis occurs through the action of the E6 and E7 oncoproteins, which inactivate the tumor suppressor genes p53 and Rb, leading to the overexpression of the p16 protein, a molecular marker widely used in HPV-induced tumors. Although the molecular mechanisms involved are well understood, prevention strategies targeting the male population, such as vaccination and viral screening, remain limited. Moreover, factors such as phimosis, inadequate genital hygiene, smoking, and coinfections contribute to viral persistence and increase the risk of neoplastic transformation, particularly in the context of structural and social vulnerabilities observed in Northern Brazil. Objective: To analyze the main risk factors associated with the development of penile cancer in Northern Brazil, with emphasis on HPV infection and its correlation with tumor aggressiveness and clinical-epidemiological characteristics. Method:This is a retrospective, cross-sectional, observational study based on secondary data extracted from the Oncology Panel of DATASUS, covering the period from January 2020 to December 2024. All records coded under ICD-10 C60 (malignant neoplasm of the penis) from the Northern region were included. The variables analyzed included age group, histological grade, clinical staging, and HPV status (when available). The data were organized in spreadsheets and analyzed using descriptive statistics, considering absolute and relative frequencies. The absence of data in key variables was documented as an indicator of the dataset’s quality. Results: During the study period, 1,954 cases of penile cancer were identified in Northern Brazil. Among these, 193 tumors classified as histological grade 4 were associated with HPV infection, suggesting a correlation between viral presence and greater tumor aggressiveness. Furthermore, HPV infection was frequently related to predisposing factors such as phimosis and chronic inflammation. A high rate of incomplete data was observed: 637 records lacked information on staging, and 945 were categorized as “not applicable,” limiting the precision of the clinical progression assessment. Conclusion: The analysis of 1,954 penile cancer cases in Northern Brazil from 2020 to 2024 revealed a significant association between HPV infection and higher tumor aggressiveness, particularly in 193 cases classified as histological grade 4. Clinical factors such as phimosis and persistent inflammation were also recurrent among HPV-positive individuals. The substantial proportion of incomplete data regarding staging highlights the urgent need to improve oncological data recording systems. These findings underscore HPV’s role as a key determinant in the severity of penile cancer and reinforce the need for more effective preventive and surveillance strategies in this vulnerable population.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
